Application of artemisinin methyl ether in preparation of medicine for treating SCA3 disease
The invention discloses application of artemisinin methyl ether in preparation of a medicine for treating SCA3 diseases, the artemisinin methyl ether is an FDA medicine for clinical application, and is high in safety, small in side effect and low in cost, so that medicine research and development can be accelerated, research and development cost can be reduced, and a new strategy is provided for development of a medicine for treating neurodegenerative diseases; researches show that artemisinin methyl ether can significantly reduce an inclusion body caused by mutant ataxin-3, improve the soluble ataxin-3 protein level, improve cell apoptosis caused by ataxin-3, and regulate and control a specific molecular mechanism of the ataxin-3 inclusion body through an HSP60/AKT signal axis. The invention aims to reveal the application of artemisinin methyl ether to exert neuroprotection on SCA3 diseases, enrich the new application of old medicines and provide a new thought for preventing and treating other neurodegenerative diseases..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 14. Apr. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
WANG ZIJIAN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-04-14, Last update posted on www.tib.eu: 2023-09-26, Last updated: 2023-09-29 |
|---|
| Patentnummer: |
CN115957210 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA002002000 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA002002000 | ||
| 003 | DE-627 | ||
| 005 | 20240327214304.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA002002000 | ||
| 035 | |a (EPA)CN115957210 | ||
| 035 | |a (EPA)87353437 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a WANG ZIJIAN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of artemisinin methyl ether in preparation of medicine for treating SCA3 disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-04-14, Last update posted on www.tib.eu: 2023-09-26, Last updated: 2023-09-29 | ||
| 520 | |a The invention discloses application of artemisinin methyl ether in preparation of a medicine for treating SCA3 diseases, the artemisinin methyl ether is an FDA medicine for clinical application, and is high in safety, small in side effect and low in cost, so that medicine research and development can be accelerated, research and development cost can be reduced, and a new strategy is provided for development of a medicine for treating neurodegenerative diseases; researches show that artemisinin methyl ether can significantly reduce an inclusion body caused by mutant ataxin-3, improve the soluble ataxin-3 protein level, improve cell apoptosis caused by ataxin-3, and regulate and control a specific molecular mechanism of the ataxin-3 inclusion body through an HSP60/AKT signal axis. The invention aims to reveal the application of artemisinin methyl ether to exert neuroprotection on SCA3 diseases, enrich the new application of old medicines and provide a new thought for preventing and treating other neurodegenerative diseases. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a WANG MIN |4 aut | |
| 700 | 0 | |a REN YUANYUAN |4 aut | |
| 700 | 0 | |a LI ZIHENG |4 aut | |
| 700 | 0 | |a LI YIRUI |4 aut | |
| 700 | 0 | |a ZUO MINGBO |4 aut | |
| 700 | 0 | |a SUN XUAN |4 aut | |
| 700 | 0 | |a GUO HUIMENG |4 aut | |
| 700 | 0 | |a CUI JIANI |4 aut | |
| 700 | 0 | |a HUO ZIRONG |4 aut | |
| 700 | 0 | |a GAO NA |4 aut | |
| 700 | 0 | |a QIN SHUAI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 14. Apr. |
| 773 | 1 | 8 | |g year:2023 |g day:14 |g month:04 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/87353437/publication/CN115957210A1?q=CN115957210 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 14 |c 04 | ||